Effect of Treatment With EGb 761(r) on Blood Markers of Inflammation and Oxidative Stress in Patients With MCI

Summary

Mild Cognitive Impairment (MCI) is the moderate impairment of a mental abilities to perform intellectual activities eg memory, calculation, communication... MCI is a disorder that can occur earlier than dementia such as Alzheimer's disease. It is believed that there are several factors involved such as inflammation and oxidative stress which is the production of reactive oxygen species that damage cells. This clinical study tries to evaluate that a treatment already approved by the AEMPS, EGb 761® (Tebofortan), could reduce the levels of markers of inflammation and oxidation in the blood.

Timeline

Start

2021-04-16

Primary completion

2023-12

Completion

2023-12

Publications

• Morato X, Marquie M, Tartari JP, Lafuente A, Abdelnour C, Alegret M, Jofresa S, Buendia M, Pancho A, Aguilera N, Ibarria M, Diego S, Cuevas R, Canada L, Calvet A, Antonio EE, Perez-Cordon A, Sanabria A, de Rojas I, Nunez-Llaves R, Cano A, Orellana A, Montrreal L, Canabate P, Rosende-Roca M, Vargas L, Bojaryn U, Ricciardi M, Ariton DM, Espinosa A, Ortega G, Munoz N, Lleonart N, Alarcon-Martin E, Moreno M, Preckler S, Tantinya N, Ramis M, Nogales AB, Seguer S, Martin E, Pytel V, Valero S, Gurruchaga M, Tarraga L, Ruiz A, Boada M. A randomized, open-label clinical trial in mild cognitive impairment with EGb 761 examining blood markers of inflammation and oxidative stress. Sci Rep. 2023 Apr 3;13(1):5406. doi: 10.1038/s41598-023-32515-6.

Drugs

Indications